FY2026 EPS Estimate for Gain Therapeutics Lifted by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX) – Stock analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research report issued on Monday, August 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.49) per share for the year, up from their previous forecast of ($0.51). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.49) EPS.

Several other equities research analysts have also commented on the stock. Weiss Ratings lowered shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. BTIG Research reaffirmed a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Oppenheimer restated an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Gain Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Gain Therapeutics Trading Down 1.7%

Shares of GANX stock opened at $1.77 on Wednesday. Gain Therapeutics has a 1-year low of $1.53 and a 1-year high of $4.34. The company has a market cap of $77.24 million, a price-to-earnings ratio of -3.54 and a beta of 0.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. The stock has a 50 day simple moving average of $1.85 and a 200-day simple moving average of $1.94.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03.

Hedge Funds Weigh In On Gain Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP boosted its holdings in shares of Gain Therapeutics by 849.3% in the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after acquiring an additional 1,487,186 shares during the period. Potomac Capital Management Inc. purchased a new position in Gain Therapeutics during the 4th quarter valued at about $3,252,000. GSA Capital Partners LLP acquired a new position in Gain Therapeutics during the second quarter worth about $1,283,000. BlackRock Inc. purchased a new stake in shares of Gain Therapeutics in the second quarter valued at about $558,000. Finally, Jane Street Group LLC increased its position in Gain Therapeutics by 234.5% during the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock worth $780,000 after buying an additional 169,878 shares in the last quarter. 11.97% of the stock is owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.